Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preface.

Nicolle1, Wise, Wood

  • 1Vienna, Austria, March 2000.

The Journal of Antimicrobial Chemotherapy
|September 2, 2000
PubMed
Summary
This summary is machine-generated.

Urinary tract infections (UTIs) are common, with increasing antibiotic resistance posing treatment challenges. Pivmecillinam offers a promising alternative due to its unique action and safety profile for managing UTIs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digitalis in Heart Diseases.

Atlanta medical and surgical journal·2022
Same author

Wood and Trees attend a conference.

Journal of the Intensive Care Society·2019
Same author

May the force be with you.

Journal of the Intensive Care Society·2018
Same author

Lemmingaid.

Journal of the Intensive Care Society·2018
Same author

Lost youth.

Journal of the Intensive Care Society·2017
Same author

General Paralysis of the Insane.

The Indian medical gazette·2017
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026
Same journal

Re-evaluating the 14-day rule: short-course antifungal therapy for uncomplicated candidaemia in a multicentre cohort study.

The Journal of antimicrobial chemotherapy·2026
Same journal

Impact of selective digestive decontamination on the pangenome composition of ESBL-E. coli.

The Journal of antimicrobial chemotherapy·2026
Same journal

Compounds of the γ-carboline family inhibit trans-translation.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Urology

Background:

  • Lower urinary tract infections (UTIs) are prevalent, accounting for significant general practitioner consultations and antibiotic prescriptions.
  • Uropathogenic bacteria exhibit increasing resistance to common antibiotics like trimethoprim and ampicillin, exceeding 30-50% in many cases.
  • Rapid development of resistance to fluoroquinolones necessitates exploring alternative treatment options for UTIs.

Purpose of the Study:

  • To review current perspectives on the diagnosis and treatment of UTIs.
  • To evaluate the role of pivmecillinam in managing UTIs amidst rising antimicrobial resistance.
  • To discuss evolving treatment strategies, including shorter regimens and alternative antibiotics.

Main Methods:

  • Review of scientific literature and clinical data on UTI treatment.

Related Experiment Videos

  • Analysis of antibiotic resistance patterns for common UTI pathogens.
  • Evaluation of pivmecillinam's pharmacological properties, including its mechanism of action, spectrum, and safety profile.

    • Main Results:

    • High rates of resistance to trimethoprim and ampicillin are observed.
    • Fluoroquinolone resistance can emerge rapidly, posing a clinical challenge.
    • Pivmecillinam demonstrates a novel mode of action, good bacterial penetration, and a favorable safety profile.

    Conclusions:

    • The changing landscape of antimicrobial resistance requires reevaluation of UTI treatment strategies.
    • Pivmecillinam's characteristics suggest it is a suitable candidate for treating common UTIs.
    • Long-term clinical experience supports reconsidering pivmecillinam's role in UTI management.